AUTHORS
Charalampia Kyriakou, MD, PhD, Maud Ngoya2, Nour Moukalled3, Irma Khvedelidze4, Mathilde Fekom, PhD5, Diane Bacabac6, Yasmina Serroukh7, Ali Bazarbachi8
AFFILIATIONS
1 University College London Hospitals NHS Foundation Trust, London, United Kingdom
2 European Bone Marrow Transplantation, Paris, France
3 American University of Beirut Medical Center, Beirut, Lebanon
4 European Bone Marrow Transplantation Lymphoma Working Party, Paris, Paris, France
5 European Society for Blood and Marrow Transplantation Office, Paris, France
6 European Bone Marrow Transplantation, Paris, France
7 Erasmus MC Cancer Institute, Rotterdam, Netherlands
8 Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Haematology, Beirut, Lebanon, Beirut, Lebanon
ABSTRACT
Introduction
Transformation of Waldenström macroglobulinaemia (WM) to high-grade lymphoma (tWM) is an uncommon but serious complication associated with poorer outcomes than indolent WM. Most patients transform to diffuse large B-cell lymphoma (DLBCL) and are treated according to DLBCL protocols. Patients who achieve an adequate response and are considered fit may proceed to consolidation with autologous (ASCT) or allogeneic stem cell transplantation. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has significantly improved response rates in aggressive B-cell lymphomas and offers the potential for durable remissions. However, evidence supporting the use of CAR T-cell therapy in tWM is limited because of the rarity of the disease and is largely restricted to small retrospective multicentre case series.
Methods
This retrospective European Society for Blood and Marrow Transplantation (EBMT) registry study evaluated outcomes following CAR T-cell therapy in patients with tWM reported to the Lymphoma Working Party (LWP) registry between 2020 and 2024. Data were collected for 78 patients from 21 EBMT centres across Europe.
Results
Among the 78 patients with tWM, treated with CAR T-cell therapy, 55 (71%) were male, with a median age of 66 years (range, 57–78). The Karnofsky Performance Status was ≥90 in 42 patients (54%). The Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) was 0 in 34 patients (51%), 1–2 in 11 (17%), and ≥3 in 21 (32%); data were unavailable for 12 patients. Disease status at the time of CAR T-cell infusion was complete remission (CR) in 11 patients (15%), partial response (PR) in 15 (21%), refractory disease (RD) in 36 (51%), stable disease (SD) in 9 (13%); disease status was unavailable for seven patients. Eleven patients (14.1%) had previously relapsed following ASCT. Lymphodepleting chemotherapy consisted of cyclophosphamide and fludarabine in 75 patients (97.4%) and bendamustine in two patients (2.6%); conditioning data were missing for one patient. After a median follow-up of 1.3 years (interquartile range, 1–2 years), the overall survival (OS) was 61% at 1 year and 55% at 2 years. Progression-free survival (PFS) was 52% at both 1 and 2 years. The cumulative incidence of relapse was 38% at both 1 and 2 years, while non-relapse mortality (NRM) was 10% at both time points. Thirty-four patients (43.5%) died during follow-up. The primary cause of death was progressive disease in 24 patients, followed by treatment-related mortality in seven and secondary malignancy in one. The cause of death was unavailable for two patients.
Conclusion
This retrospective EBMT registry study suggests that CAR T-cell therapy is an effective salvage treatment for patients with active tWM, with encouraging survival outcomes. Given the rarity of tWM, larger collaborative registry and prospective studies are required to better define the optimal role and the timing of CAR T-cell therapy.
DISCLOSURES
Charalampia Kyriakou, MD, PhD: No relevant conflicts of interest to declare.